A PHASE III PROSPECTIVE RANDOMIZED STUDY OF CRANIOSPINAL RADIOTHERAPY FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS (CCNU, CDDP, VCR OR CPM, CDDP, VCR) IN CHILDREN WITH NEWLY-DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA
OBJECTIVES: I. Assess whether a cyclophosphamide-containing combination chemotherapy regimen
increases progression-free survival compared to a lomustine-containing regimen in children
with newly diagnosed, average-risk medulloblastoma. II. Determine progression-free and
overall survival of children treated with craniospinal radiotherapy and local boost
radiotherapy for a total dose of 5580 cGy followed by adjuvant
lomustine/cisplatin/vincristine vs. cyclophosphamide/cisplatin/vincristine. III. Determine
the long-term neurocognitive, endocrinologic, and cardiopulmonary sequelae associated with
craniospinal radiotherapy, local boost radiotherapy, and adjuvant chemotherapy in these
children, and determine whether replacement of lomustine with cyclophosphamide alters the
incidence and degree of sequelae. IV. Determine whether cellular and biologic parameters,
including tumor molecular genetic analysis, DNA ploidy, mitotic activity markers, and
immunohistochemical analysis, are correlated with progression-free survival, overall
survival, and patterns of disease relapse in these patients. V. Evaluate the utility of
routine magnetic resonance imaging surveillance studies of the head and spine in detecting
subclinical recurrent disease.
OUTLINE: This is a randomized study. Patients are stratified by participating institution.
Following surgery, patients are randomized to one of two groups. The first group receives
craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week
after initiation of radiotherapy, patients receive vincristine weekly for 8 doses. Beginning
6 weeks after the completion of radiotherapy, patients receive adjuvant
lomustine/vincristine/cisplatin every 6 weeks for a total of 8 courses. The second group
receives craniospinal irradiation plus vincristine as above, followed by adjuvant
cyclophosphamide/vincristine/cisplatin every 6 weeks for a total of 8 courses. Patients are
followed every 3 months for 1 year, every 6 months for 2 years, then annually.
PROJECTED ACCRUAL: It is anticipated that 240-300 patients will be entered over 4 years.
Interventional
Allocation: Randomized, Primary Purpose: Treatment
Roger J. Packer, MD
Study Chair
Children's Research Institute
United States: Federal Government
CDR0000065160
NCT00002875
December 1996
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |
University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109-0752 |
Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Jonsson Comprehensive Cancer Center, UCLA | Los Angeles, California 90095-1781 |
University of Chicago Cancer Research Center | Chicago, Illinois 60637 |
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
University of Iowa Hospitals and Clinics | Iowa City, Iowa 52242 |
University of Minnesota Cancer Center | Minneapolis, Minnesota 55455 |
Lineberger Comprehensive Cancer Center, UNC | Chapel Hill, North Carolina 27599-7295 |
Ireland Cancer Center | Cleveland, Ohio 44106-5065 |
Cancer Center, University of Virginia HSC | Charlottesville, Virginia 22908 |
MBCCOP - LSU Medical Center | New Orleans, Louisiana 70112 |
UCSF Cancer Center and Cancer Research Institute | San Francisco, California 94115-0128 |
Vanderbilt Cancer Center | Nashville, Tennessee 37232-6838 |
NYU School of Medicine's Kaplan Comprehensive Cancer Center | New York, New York 10016 |
Huntsman Cancer Institute | Salt Lake City, Utah 84112 |
University of Wisconsin Comprehensive Cancer Center | Madison, Wisconsin 53792 |
Herbert Irving Comprehensive Cancer Center | New York, New York 10032 |
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
Long Beach Memorial Medical Center | Long Beach, California 90806 |
Children's Hospital Los Angeles | Los Angeles, California 90027-0700 |
Children's Hospital of Orange County | Orange, California 92668 |
Children's Hospital of Denver | Denver, Colorado 80218 |
Children's National Medical Center | Washington, District of Columbia 20010-2970 |
Children's Mercy Hospital | Kansas City, Missouri 64108 |
St. Joseph's Hospital and Medical Center | Paterson, New Jersey 07503 |
Children's Hospital Medical Center - Cincinnati | Cincinnati, Ohio 45229-3039 |
Children's Hospital of Columbus | Columbus, Ohio 43205-2696 |
Doernbecher Children's Hospital | Portland, Oregon 97201-3098 |
Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania 15213 |
Children's Hospital and Regional Medical Center - Seattle | Seattle, Washington 98105 |
Via Christi Regional Medical Center | Wichita, Kansas 67214 |
Saint Jude Children's Research Hospital | Memphis, Tennessee 38105-2794 |